Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2019)
16 slides from Orion Oyj Class A's investor day presentation, May 22, 2019
Slide 1: Orion Capital Markets Day 2019
Orion Capital Markets Day 2019 Welcome!
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Your hosts today
Your hosts today Satu Ahomäki Markku Timo Lappalainen Commercial Operations, Olli Huotari Global Sales & Huhta-Koivisto President and CEO Corporate Functions Proprietary Products Growth Projects Liisa Hurme Jari Karlson Virve Laitinen Christer Nordstedt Prof. Supply Chain CFO, Animal Health Specialt
Slide 4: Our agenda
Our agenda Timo Lappalainen Welcome President & CEO Orion 2025: Paths towards the growth target Jari Karlson Ambitious growth target with high profitability CFO Christer Nordstedt, SVP, Research & Development R&D - The key engine for profitable growth Prof. Heikki Joensuu, Vice President, Oncology,
Slide 5: Orion 2025: Paths towards the growth target
Orion 2025: Paths towards the growth target Timo Lappalainen President and CEO
Slide 6: Orion at a glance (2018 figures)
Orion at a glance (2018 figures) Net sales Sales by business Sales by market area 977 MEUR Operating profit 5% 2% 15% 8% 253 MEUR 37% 32% 6% Personnel 3,154 R&D investments 48% 104 MEUR 31% 16% 6 production sites in Finland Proprietary Products Finland Specialty Products Scandinavia Own sales unit A
Slide 7: Key strategic target: Growing more rapidly than the market
Key strategic target: Growing more rapidly than the market - Increasing investments to support growth 1 Net sales target in 2025 Own investments in new clinical trials: Investments in sales and marketing: 1.5 E.g. EUR 60 million E.g. strengthening investment in the Easyhaler Phase III trial on ALS p
Slide 8: Value creation by business
Value creation by business Proprietary Products Specialty Products • IPR & patents • Strong market position & economies of • Sharpened focus of competencies scale • Investment in R&D • Focused markets • In-licensing • Orion brand • Cost-efficient operating model Animal Health Fermion • Treatment of
Slide 9: Several global megatrends are boosting the demand
Several global megatrends are boosting the demand Increased personal Ageing Cost burden in Advancement responsibility Sustainability population health care in science for health Capital Markets Day of Orion Corporation © Orion Oyj 22 May 2019 9
Slide 10: Global operating environment: The average growth of the pharmaceutical market is 3-6% annually
Global operating environment: The average growth of the pharmaceutical market is 3-6% annually The United States will retain +3-6% its position as the largest market. Growth is fastest in Global market in 2023 +1-4% 15% emerging markets. USD 1 505-1 535 billion Europe, 5 largest -3-0% 6% USD 195-225
Slide 11: Growth driven by R&D and Proprietary Products
Growth driven by R&D and Proprietary Products • Maximise current portfolio • Darolutamide M0 • Successful commercialization of • Darolutamide M1 pipeline products • ODM-109 • Utilise in-licensing opportunities Proprietary R&D • Animal Health projects Products Animal Health: • Maintain solid profitab
Slide 12: Key themes of corporate responsibility
Key themes of corporate responsibility Responsibility Ensure patient for the environment Ethics and safety and – production according Taking care of transparency of availability of to the principles Orionees operations medicines of sustainable development Capital Markets Day of Orion Corporation © O
Slide 13: This is how we are building well-being responsibly
This is how we are building well-being responsibly WE PRODUCE 1/3 OF THE GLOBAL SUPPLY OF ~200-300 NUMBER OF AUDITS CUSTOMER METHOTREXATE ANNUALLY COMPLAINTS IN 2018 56 (ppm) ORION’S FOCUS ON QUALITY THROUGHOUT THE LIFECYCLE PATIENT R&D RAW MANUFACTURING PACKING DELIVERY SALES PATIENT RECYCLING NEED
Slide 14: Orion creates shareholder value also through dividends
Orion creates shareholder value also through dividends • While Orion invests in 1,75 growth, we will also highly 0.12 1,50 value the ability to pay 0.06 dividends. 1,25 0.10 • Orion’s financial objective 1,00 is to distribute an annual 0,75 dividend that in the next few years will be at least 0,50 E
Slide 15: …with a healthy total return for shareholders
…with a healthy total return for shareholders Last 5 years* TSR for the last 5 years +70% +50% stock price increase +19% dividend return Average annual TSR is +11.1% Last 10 years* TSR for the last 10 years +365% +214% stock price increase +151% dividend return Average annual TSR is +16.6% *)All TSR
Slide 16: Thank you!
Thank you! Building well-being